Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 1
2018 1
2019 5
2020 7
2021 14
2022 12
2023 9
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

42 results

Results by year

Filters applied: . Clear all
Page 1
Joint EANM/SNMMI procedure guideline for the use of (177)Lu-labeled PSMA-targeted radioligand-therapy ((177)Lu-PSMA-RLT).
Kratochwil C, Fendler WP, Eiber M, Hofman MS, Emmett L, Calais J, Osborne JR, Iravani A, Koo P, Lindenberg L, Baum RP, Bozkurt MF, Delgado Bolton RC, Ezziddin S, Forrer F, Hicks RJ, Hope TA, Kabasakal L, Konijnenberg M, Kopka K, Lassmann M, Mottaghy FM, Oyen WJG, Rahbar K, Schoder H, Virgolini I, Bodei L, Fanti S, Haberkorn U, Hermann K. Kratochwil C, et al. Eur J Nucl Med Mol Imaging. 2023 Jul;50(9):2830-2845. doi: 10.1007/s00259-023-06255-8. Epub 2023 May 29. Eur J Nucl Med Mol Imaging. 2023. PMID: 37246997 Free PMC article.
Prostate-specific membrane antigen (PSMA) is expressed by the majority of clinically significant prostate adenocarcinomas, and patients with target-positive disease can easily be identified by PSMA PET imaging. ...Hence, the radiopharmaceuticals [(177)Lu]Lu-PSMA …
Prostate-specific membrane antigen (PSMA) is expressed by the majority of clinically significant prostate adenocarcinomas, and patien …
EANM procedure guidelines for radionuclide therapy with (177)Lu-labelled PSMA-ligands ((177)Lu-PSMA-RLT).
Kratochwil C, Fendler WP, Eiber M, Baum R, Bozkurt MF, Czernin J, Delgado Bolton RC, Ezziddin S, Forrer F, Hicks RJ, Hope TA, Kabasakal L, Konijnenberg M, Kopka K, Lassmann M, Mottaghy FM, Oyen W, Rahbar K, Schöder H, Virgolini I, Wester HJ, Bodei L, Fanti S, Haberkorn U, Herrmann K. Kratochwil C, et al. Eur J Nucl Med Mol Imaging. 2019 Nov;46(12):2536-2544. doi: 10.1007/s00259-019-04485-3. Epub 2019 Aug 22. Eur J Nucl Med Mol Imaging. 2019. PMID: 31440799
Prostate-specific membrane antigen (PSMA) is expressed in most prostate cancers and can be identified by PSMA-ligand imaging, which has already become clinically accepted in several countries in- and outside Europe. PSMA-directed radioligand therapy (PSMA …
Prostate-specific membrane antigen (PSMA) is expressed in most prostate cancers and can be identified by PSMA-ligand imaging, …
New Horizons in Radioligand Therapy: 161Tb-PSMA-617 in Advanced mCRPC.
Rosar F, Maus S, Schaefer-Schuler A, Burgard C, Khreish F, Ezziddin S. Rosar F, et al. Clin Nucl Med. 2023 May 1;48(5):433-434. doi: 10.1097/RLU.0000000000004589. Epub 2023 Feb 8. Clin Nucl Med. 2023. PMID: 36758550
This one administration of 6.5 GBq 161 Tb-PSMA-617 resulted in impressive partial remission with a PSA decline by 53.4% (from 474 to 221 ng/mL) and a concomitant decrease in tumor burden on PSMA PET/CT imaging. The presented case provides stunning initial evidence o …
This one administration of 6.5 GBq 161 Tb-PSMA-617 resulted in impressive partial remission with a PSA decline by 53.4% (from 474 to …
PSMA-RLT in Patients with Metastatic Hormone-Sensitive Prostate Cancer: A Retrospective Study.
Banda A, Privé BM, Allach Y, Uijen MJM, Peters SMB, Loeff CC, Gotthardt M, Muselaers CHJ, Witjes JA, van Oort IM, Sedelaar JPM, Westdorp H, Mehra N, Khreish F, Ezziddin S, Sabet A, Kreissl MC, Winkens T, Seifert P, Janssen MJR, van Gemert WAM, Nagarajah J. Banda A, et al. Cancers (Basel). 2022 Dec 31;15(1):297. doi: 10.3390/cancers15010297. Cancers (Basel). 2022. PMID: 36612293 Free PMC article.
Given the mode of action, patients in an earlier disease stage, such as hormone-sensitive prostate cancer (HSPC), are also likely to benefit from [(177)Lu]Lu-PSMA- ((177)Lu-PSMA) or [(225)Ac]Ac-PSMA-radioligand treatment ((225)Ac-PSMA). ...RESULTS: In …
Given the mode of action, patients in an earlier disease stage, such as hormone-sensitive prostate cancer (HSPC), are also likely to benefit …
(225)Ac-PSMA-617/(177)Lu-PSMA-617 tandem therapy of metastatic castration-resistant prostate cancer: pilot experience.
Khreish F, Ebert N, Ries M, Maus S, Rosar F, Bohnenberger H, Stemler T, Saar M, Bartholomä M, Ezziddin S. Khreish F, et al. Eur J Nucl Med Mol Imaging. 2020 Mar;47(3):721-728. doi: 10.1007/s00259-019-04612-0. Epub 2019 Nov 22. Eur J Nucl Med Mol Imaging. 2020. PMID: 31758224
METHODS: We retrospectively analyzed pilot experience with 1 course of (225)Ac-PSMA-617/(177)Lu-PSMA-617 tandem therapy in our first 20 patients with mCRPC receiving this intervention after insufficiently responding to (177)Lu-PSMA-617 monotherapy. ...RESULTS …
METHODS: We retrospectively analyzed pilot experience with 1 course of (225)Ac-PSMA-617/(177)Lu-PSMA-617 tandem therapy in our …
Neuron-specific enolase has potential value as a biomarker for [(18)F]FDG/[(68)Ga]Ga-PSMA-11 PET mismatch findings in advanced mCRPC patients.
Rosar F, Ribbat K, Ries M, Linxweiler J, Bartholomä M, Maus S, Schreckenberger M, Ezziddin S, Khreish F. Rosar F, et al. EJNMMI Res. 2020 May 24;10(1):52. doi: 10.1186/s13550-020-00640-2. EJNMMI Res. 2020. PMID: 32449086 Free PMC article.
BACKGROUND: PSMA-targeted radioligand therapy (PSMA-RLT) yielded impressive results in the metastasized castration-resistant prostate carcinoma (mCRPC) setting. High expression of PSMA is essential for successful PSMA-RLT. However, some patients develo …
BACKGROUND: PSMA-targeted radioligand therapy (PSMA-RLT) yielded impressive results in the metastasized castration-resistant p …
Upregulation of PSMA Expression by Enzalutamide in Patients with Advanced mCRPC.
Rosar F, Neher R, Burgard C, Linxweiler J, Schreckenberger M, Hoffmann MA, Bartholomä M, Khreish F, Ezziddin S. Rosar F, et al. Cancers (Basel). 2022 Mar 26;14(7):1696. doi: 10.3390/cancers14071696. Cancers (Basel). 2022. PMID: 35406467 Free PMC article.
Imaging results were compared based on quantification of whole-body PSMA tumor burden: total lesion PSMA (TLP) and normalized TLP values to liver (TLP-LR) and to parotid gland (TLP-PR). ...The relative PSMA upregulation effect seems to be more pronounced in l …
Imaging results were compared based on quantification of whole-body PSMA tumor burden: total lesion PSMA (TLP) and normalized …
Detection Efficacy of (68)Ga-PSMA-11 PET/CT in Biochemical Recurrence of Prostate Cancer with Very Low PSA Levels: A 7-Year, Two-Center "Real-World" Experience.
Burgard C, Hoffmann MA, Frei M, Buchholz HG, Khreish F, Marlowe RJ, Schreckenberger M, Ezziddin S, Rosar F. Burgard C, et al. Cancers (Basel). 2023 Feb 21;15(5):1376. doi: 10.3390/cancers15051376. Cancers (Basel). 2023. PMID: 36900169 Free PMC article.
Gallium-68 prostate-specific membrane antigen-11 positron emission tomography/computed tomography ((68)Ga-PSMA-11 PET/CT) detection rates of lesions suspicious for prostate cancer are well known to rise along with prostate-specific antigen (PSA) concentration. ...Given the …
Gallium-68 prostate-specific membrane antigen-11 positron emission tomography/computed tomography ((68)Ga-PSMA-11 PET/CT) detection r …
Current status and future perspectives of PSMA-targeted therapy in Europe: opportunity knocks.
Pfestroff A, Luster M, Jilg CA, Olbert PJ, Ohlmann CH, Lassmann M, Maecke HR, Ezziddin S, Bodei L; Radionuclide Therapy Committee of the European Association of Nuclear Medicine. Pfestroff A, et al. Eur J Nucl Med Mol Imaging. 2015 Dec;42(13):1971-5. doi: 10.1007/s00259-015-3186-3. Eur J Nucl Med Mol Imaging. 2015. PMID: 26373947 No abstract available.
(89)Zr-labeled PSMA ligands for pharmacokinetic PET imaging and dosimetry of PSMA-617 and PSMA-I&T: a preclinical evaluation and first in man.
Privé BM, Derks YHW, Rosar F, Franssen GM, Peters SMB, Khreish F, Bartholomä M, Maus S, Gotthardt M, Laverman P, Konijnenberg MW, Ezziddin S, Nagarajah J, Heskamp S. Privé BM, et al. Eur J Nucl Med Mol Imaging. 2022 May;49(6):2064-2076. doi: 10.1007/s00259-021-05661-0. Epub 2021 Dec 21. Eur J Nucl Med Mol Imaging. 2022. PMID: 34932154
We compared the biodistribution of (89)Zr-PSMA-617 and (89)Zr-PSMA-I&T to those of (177)Lu-PSMA-617 and (177)Lu-PSMA-I&T, respectively, in a PSMA(+) xenograft model. ...For biodistribution, BALB/c nude mice bearing PSMA(+) and …
We compared the biodistribution of (89)Zr-PSMA-617 and (89)Zr-PSMA-I&T to those of (177)Lu-PSMA-617 and (177)Lu- …
42 results